ZOMETA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZOMETA (ZOMETA).
Zoledronic acid is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), thereby preventing the prenylation of small GTPase signaling proteins essential for osteoclast activity.
| Metabolism | Zoledronic acid is not metabolized and is excreted unchanged primarily by the kidneys via glomerular filtration and tubular secretion. |
| Excretion | Renal: 50-60% of the dose excreted unchanged in urine within 24 hours; terminal elimination involves slow release from bone with subsequent renal excretion; biliary/fecal excretion is minimal (<5%). |
| Half-life | Terminal elimination half-life is approximately 146 hours (6.1 days) due to prolonged release from bone; clinical context: supports monthly dosing for osteoporosis and quarterly for Paget's disease. |
| Protein binding | Approximately 22-33% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.8-1.0 L/kg, indicating extensive distribution into bone and soft tissues; clinical meaning: large Vd reflects high bone affinity. |
| Bioavailability | Intravenous: 100% (only route of administration); oral bioavailability is negligible (<5%) due to poor absorption and binding to dietary calcium. |
| Onset of Action | Intravenous infusion: Reduction in bone resorption markers (e.g., NTX) observed within 24-48 hours; clinical effect on hypercalcemia occurs within 2-4 days. |
| Duration of Action | Bone resorption suppression persists for up to 3 weeks after a single dose; clinical effect on hypercalcemia may last 7-14 days; repeat dosing typically every 4 weeks for osteoporosis. |
4 mg IV over 15 minutes every 3-4 weeks for hypercalcemia of malignancy or bone metastases.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in CrCl <35 mL/min. For CrCl 35-60 mL/min: reduce dose to 3 mg. No adjustment needed for CrCl >60 mL/min. |
| Liver impairment | No specific dose adjustments for hepatic impairment. Use caution in severe hepatic impairment. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; monitor renal function and electrolytes closely due to age-related decline in renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZOMETA (ZOMETA).
| Breastfeeding | Unknown if zoledronic acid is excreted in human milk; M/P ratio not established. Because of potential for bone growth suppression in the infant, breastfeeding is not recommended during ZOMETA therapy. Discontinue drug or nursing based on importance to mother. |
| Teratogenic Risk | ZOMETA (zoledronic acid) is contraindicated in pregnancy. Based on animal studies and its mechanism of action (bisphosphonate), there is potential for fetal harm. In the first trimester, there may be risk of skeletal and organ abnormalities due to inhibition of bone resorption. In second and third trimesters, fetal bone development may be impaired, leading to hypocalcemia, skeletal retardation, and low birth weight. Human data are limited; however, bisphosphonates cross the placenta and accumulate in fetal bone. |
■ FDA Black Box Warning
Renal toxicity: Zometa has been associated with renal toxicity, particularly in patients with pre-existing renal impairment or when used in conjunction with other nephrotoxic drugs. Osteonecrosis of the jaw (ONJ): Increased risk with invasive dental procedures and longer treatment duration.
| Common Effects | Diarrhea Nausea Vomiting Flatulence |
| Serious Effects |
Hypersensitivity to zoledronic acid or any component. Hypocalcemia. Severe renal impairment (CrCl <35 mL/min). Pregnancy (potential fetal harm).
| Precautions | Monitor renal function before and during therapy; assess serum creatinine. Osteonecrosis of the jaw: perform dental exam before treatment. Atypical femur fractures: evaluate for thigh or groin pain. Hypocalcemia: correct before initiation. Severe musculoskeletal pain. Not recommended in severe renal impairment (CrCl <35 mL/min). |
Loading safety data…
| Fetal Monitoring | Monitor serum calcium, phosphate, magnesium, and creatinine before and during infusion. Assess renal function regularly. Measure fetal growth via ultrasound if inadvertent exposure in pregnancy. Monitor for maternal hypocalcemia and osteomalacia. In fetuses, monitor for skeletal abnormalities and hypocalcemia. |
| Fertility Effects | Zoledronic acid may impair fertility. In animal studies, high doses caused reduced fertility and preimplantation losses in rats. In humans, no formal studies; but bisphosphonates can cause ovarian toxicity and potentially reduce fertility. Advise women of reproductive potential to use effective contraception during therapy and for a period after discontinuation. |